HER2 status in breast cancer: Experience of a Spanish National Reference Centre

Clinical and Translational Oncology

Volumn 13, Issue 5, 2011, Pages 335-340

  Cuadros, Marta ^a,b   Cano, Carlos ^a   López, Francisco Javier ^a   Talavera, Paloma ^b   García Peréz, Inmaculada ^b   Blanco, Armando ^a   Concha, Ángel ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Breast neoplasms; Descriptive analysis; Fluorescence; HER2; Immunohistochemistry; In situ hybridisation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CHROMOSOME 17; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NUMERICAL CHROMOSOME ABERRATION; POLYSOMY 17; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SPAIN; TREATMENT OUTCOME;

EID: 79960669645     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0663-4     Document Type: Article

References (23)

1. Ferlay J, Bray F, Pisani P, Parkin DM (2004) LOBOCAN 2002: cancer incidence, mortality and prevalence worldwide [IARC CancerBase No 5, version 20]. IARC Press, Lyon
2. Pollan M, Ramis R, Aragones N et al (2007) Municipal distribution of breast cancer mortality among women in Spain. BMC Cancer 7:78
3. Esteva FJ, Sahin AA, Cristofanilli M et al (2002) Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12: 319-328 (Pubitemid 35204822)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
5. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in fi rst-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726 (Pubitemid 34111379)
6. Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323-1333
7. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California Cancer Registry. Cancer 109:1721-1728. (Pubitemid 46668532)
8. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044 (Pubitemid 46638799)
9. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18
10. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
11. Al-Dujaily EA, Al-Janabi AA, Pierscionek T, Yasseen AA (2008) High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium. J Carcinog 7:8
12. Kitano Y, Umemura S, Ohbayashi H et al (2007) Assessment of a new anti-HER2 monoclonal antibody, SV2-61gamma: a best concordance with HER2 FISH. Appl Immunohistochem Mol Morphol 15:389-393 (Pubitemid 350307843)
13. Dybdal N, Leiberman G, Anderson S et al (2005) Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93:3-11 (Pubitemid 41355986)
14. Tsuda H, Akiyama F, Terasaki H et al (2001) Detection of HER-2/neu (c-erb B-2) DNA amplifi cation in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92:2965-2974 (Pubitemid 33136190)
15. Cuadros M, Talavera P, López FJ et al (2010) Realtime RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 77:38-45
16. Merola R, Mottolese M, Orlandi G et al (2006) Analysis of aneusomy level and HER-2 gene copy number and their effect on amplifi cation rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42:1501-1506 (Pubitemid 43903166)
17. Downs-Kelly E, Yoder BJ, Stoler M et al (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fl uorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221-1227 (Pubitemid 41232996)
18. Hyun CL, Lee HE, Kim KS et al (2008) The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61:317-321 (Pubitemid 351354237)
19. Zhao J, Wu R, Au A et al (2002) Determination of HER2 gene amplifi cation by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15:657-665 (Pubitemid 34666470)
20. Chibon F, de Mascarel I, Sierankowski G et al (2009) Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol 22:403-409
21. Vanden Bempt I, Van Loo P, Drijkoningen M et al (2008) Polysomy 17 in breast cancer: clinicopathologic signifi cance and impact on HER-2 testing. Clin Oncol 26:4869-4874
22. Lal P, Salazar PA, Ladanyi M, Chen B (2003) Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplifi cation. Mol Diagn 5:155-159 (Pubitemid 36974726)
23. Moriki T, Takahashi T, Ueta S et al (2004) Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fi xed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol 30:251-256 (Pubitemid 38420243)